• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction].

作者信息

Liang Feng, Wang Li-zhong, Hu Da-yi, Shi Xu-bo, Wei Jia-ping, Zhao Hong, Wang Lei, Jia San-qing, Wang Hong-yu, Liu Ru-hui, Chen Yun-dai, Lu Yan-ling

机构信息

Department of Cardiology, Beijing Daxing Hospital, Capital University of Medical Sciences, Beijing 102600, China.

出版信息

Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Jun;37(6):514-7.

PMID:19927632
Abstract

OBJECTIVE

In this randomized, open-label, multicenter, angiographic trial, we compared the efficacy and safety of tenecteplase (TNK-tPA) with alteplase (rt-PA) in Chinese patients with acute myocardial infarction.

METHOD

Patients with acute ST-elevation myocardial infarction and pain to hospital time within 6 hours from October 2002, to March 2004 were randomly assigned a body weight-adjusted bolus of TNK-tPA (0.53 mg/kg over more than 10 s, n = 58) or front loaded rt-PA (< or = 100 mg, n = 52). Coronary angiography was performed at 90 min after initiating study drugs. All patients received aspirin and heparin (target activated partial thromboplastin time: 50-70 s). The primary end point of the trial was the rate of TIMI grade 3 flow at 90 minutes. Other end points included the rate of TIMI grade 2/3 flow at 90 minutes, all cause mortality at 30 days, the moderate/severe hemorrhage without intracranial hemorrhage (ICH) and ICH within 30 days.

RESULTS

TIMI grade 3 flow at 90 minutes (68.4% vs. 66.7%, P = 1.00), TIMI grade 2 or 3 at 90 minutes (89.5% vs. 80.4%, P = 0.278), total mortality at 30 days (13.8% vs. 9.6%, P = 0.565), the rate of moderate/severe hemorrhage (8.6% vs. 5.8%, P = 0.72) and incidence of ICH (3.5% vs. 1.9%, P = 1.00) were all similar in TNK-tPA treated patients compared to rt-PA treated patients.

CONCLUSION

The efficacy of single-bolus, weight-adjusted TNK-tPA fibrinolytic regimen is equivalent to front-loaded alteplase in terms of the rates of TIMI grade 3 flow, TIMI 2 or 3 flow. Incidences of moderate/severe hemorrhage, ICH and 30-days mortality were similar in TNK-tPA and rt-PA treated patients.

摘要

相似文献

1
[An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction].
Zhonghua Xin Xue Guan Bing Za Zhi. 2009 Jun;37(6):514-7.
2
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.急性心肌梗死中替奈普酶与加速型阿替普酶对比:心肌梗死溶栓治疗(TIMI)10B试验结果。心肌梗死溶栓治疗(TIMI)10B研究组
Circulation. 1998;98(25):2805-14. doi: 10.1161/01.cir.98.25.2805.
3
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial.依替巴肽与小剂量替奈普酶联合再灌注治疗ST段抬高型心肌梗死:急性心肌梗死中依替巴肽与替奈普酶(INTEGRITI)II期血管造影试验结果
J Am Coll Cardiol. 2003 Apr 16;41(8):1251-60. doi: 10.1016/s0735-1097(03)00123-2.
4
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.纤维蛋白特异性溶栓剂在急性心肌梗死中无反常凝血酶激活:单次推注替奈普酶与先予负荷量阿替普酶的比较
Thromb Res. 2002 Apr 15;106(2):113-9. doi: 10.1016/s0049-3848(02)00084-1.
5
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.急性心肌梗死中替奈普酶-组织型纤溶酶原激活剂。心肌梗死溶栓治疗(TIMI)10A剂量范围试验的结果。
Circulation. 1997 Jan 21;95(2):351-6. doi: 10.1161/01.cir.95.2.351.
6
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Eur Heart J. 2001 Dec;22(24):2253-61. doi: 10.1053/euhj.2001.2686.
7
Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.替奈普酶:急性心肌梗死患者的药理学及治疗效果综述
Am J Cardiovasc Drugs. 2001;1(1):51-66. doi: 10.2165/00129784-200101010-00006.
8
Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.急性心肌梗死治疗期间,前负荷型阿替普酶与单剂量突变体替奈普酶和拉诺替普酶的纤溶活性比较
Am Heart J. 2003 Feb;145(2):217-25. doi: 10.1067/mhj.2003.110.
9
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
Am Heart J. 1999 May;137(5):786-91. doi: 10.1016/s0002-8703(99)70400-x.
10
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.心肌梗死溶栓治疗10B试验中替奈普酶组织型纤溶酶原激活剂的体重调整剂量及其与血管造影结果的关系。TIMI 10B研究人员。
Am J Cardiol. 1999 Nov 1;84(9):976-80. doi: 10.1016/s0002-9149(99)00483-x.

引用本文的文献

1
Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis.急性心肌梗死患者组织型纤溶酶原激活物的不良反应:真实世界和药物警戒数据库分析。
BMC Cardiovasc Disord. 2024 Aug 23;24(1):441. doi: 10.1186/s12872-024-04121-5.
2
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?使用替奈普酶治疗急性缺血性脑卒中:为何还未普及?
West J Emerg Med. 2020 Feb 24;21(2):199-202. doi: 10.5811/westjem.2020.1.45279.
3
Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
替奈普酶与阿替普酶治疗急性冠状动脉综合征的安全性和有效性:一项随机试验的系统评价和荟萃分析
Arch Med Sci. 2016 Dec 1;12(6):1181-1187. doi: 10.5114/aoms.2016.58929. Epub 2016 Mar 31.